Intracranial Catheter Placement

PROCEDURE3 trials

Sponsors

Mayo Clinic, City of Hope Medical Center

Conditions

Brain NeoplasmsRecurrent Astrocytoma, IDH-Mutant, Grade 3Recurrent Astrocytoma, IDH-Mutant, Grade 4Recurrent GlioblastomaRecurrent Glioblastoma, IDH-Wildtype

Phase 1

Intracranial Genetically Modified Immune Cells (TGFβR2KO/IL13Rα2 CAR T-Cells) for the Treatment of Recurrent or Progressive Glioblastoma or Grade 3 or 4 IDH-Mutant Astrocytoma

RecruitingNCT06815029

City of Hope Medical CenterRecurrent Astrocytoma, IDH-Mutant, Grade 3, Recurrent Astrocytoma, IDH-Mutant, Grade 4, Recurrent Glioblastoma

Start: 2025-06-17End: 2030-10-11Target: 27Updated: 2025-06-26

Locoregional Administration of Genetically Engineered Cells (EGFR/IL13Rα2 Pool-CAR T Cells) for the Treatment of Recurrent or Progressive High-Grade Gliomas

RecruitingNCT07544992

City of Hope Medical CenterRecurrent Astrocytoma, IDH-Mutant, Grade 4, Recurrent Glioblastoma, IDH-Wildtype

Start: 2026-12-24End: 2031-11-04Target: 24Updated: 2026-05-06

Unknown Phase

Ommaya Reservoir Placement at the Time of Biopsy for Longitudinal Biomarker Collection in Patients With Brain Tumors

RecruitingNCT06322602

Mayo ClinicBrain Neoplasms

Start: 2024-02-28End: 2029-03-01Target: 20Updated: 2026-03-03